Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Eden vs FORM by GBY

Two GLP-1 desks, one scoreboard. We put Eden and FORM by GBY head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 3 · Grade A−

Eden

Visit Eden Full brief →
vs
No. 199 · Grade C

FORM by GBY

Visit FORM by GBY Full brief →

The verdict

Eden takes this head-to-head.

Eden scores 91 to 67 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.

That doesn't make FORM by GBY a bad call — it's best for readers who want the widest single-account menu and are willing to complete intake to learn what the branded and adjacent-care lines actually cost. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
89
55
Supply Reliability
92
78
Transparency
93
42
Access Breadth
90
82
Clinical Oversight
92
60
Track Record
89
68
EdenBrief Score 91 · 67FORM by GBY

Price, coverage & the tracker

EdenFORM by GBY
Brief Score91/100 (A−)67/100 (C)
Semaglutide$239/mo$299/mo (compounded, no dose tiers published)
Tirzepatide$349/moNot disclosed (Zepbound membership offered, drug cost not published)
CoverageAll 50 states48 states + DC (excludes Alaska, Mississippi)
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.

FORM by GBY: First reading — one real price (compounded sema $299); everything else, including the advertised Wegovy "$95," is a membership fee or undisclosed.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.